Monitor upcoming medical conference presentations for additional Week 52 data and regulatory discussions later this year, which will shape the registration-directed program's scope. The $200M cash cushion removes near-term financing overhang, allowing focus on execution.
Drug in focus
QTTB drug pipeline →bempikibart
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
- Next catalyst
- None dated
What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $16.49entry
- T+1 · 3mo ago −1.76%α −1.60% · $16.20
- T+5 · 3mo ago −6.79%α −7.14% · $15.37
- T+20 · 3mo ago −17.59%α −16.98% · $13.59
- T+60 · 19d ago −46.21%α −46.15% · $8.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe alopecia areata, demonstrating a 35.3% mean SALT reduction and 40% SALT-20 response rate (mITT) with a favorable safety profile. The company completed a $200M public offering in July 2026, extending cash runway through Phase 3 topline results from a planned registration-directed program expected to initiate in H1 2027. This filing confirms a major clinical catalyst and strong capitalization for a pivotal program.
Key Financial Metrics
Key Facts
- Bempikibart achieved 35.3% mean SALT reduction from baseline at Week 36 (mITT) and 40% SALT-20 response rate; well-tolerated with no new safety signals.
- Registration-directed program in severe/very severe AA expected to initiate in H1 2027 subject to regulatory discussions in H2 2026.
- Completed $200M public offering in July 2026, raising gross proceeds before expenses.
- Cash and cash equivalents were $106.3M as of June 30, 2026, plus offering proceeds expected to fund through Phase 3 topline results.
- Venture debt of $9.7M fully repaid, net debt zero at June 30, 2026.
- Net loss for Q2 2026 was $8.9M ($0.44 per share) vs $9.5M ($0.78 per share) in Q2 2025, improving due to lower R&D spend.
Financial Impact
Positive Phase 2a data and $200M offering materially de-risk the pivotal program; stock likely to re-rate on clinical success and extended runway.
Risk Factors
- Phase 2a data is open-label and may not fully predict Phase 3 success; durability and safety in longer follow-up remain key.
- Dilution from $200M equity offering pressures near-term valuation.
- Competition from approved JAK inhibitors (e.g., Olumiant) in AA; differentiation needed on safety and durability.
- Regulatory path timelines may slip; FDA feedback could require additional studies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333813 |
| Document: qttb-20260805.htm | 0001193125-26-333813 |
| Document: 0001193125-26-333813-index-headers.html | 0001193125-26-333813 |
| Document: 0001193125-26-333813-index.html | 0001193125-26-333813 |
| Document: 0001193125-26-333813.txt | 0001193125-26-333813 |
| 8-K Data (Synthetic) | 0001193125-26-333813 |
Track record
23 reports on QTTB
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
- Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
- Sep 14, 20269w ago 8-K Neutral 3/10 Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers